The European Commission approval of pembrolizumab for 1L R/M SCCHN indicates its use as a monotherapy or in combination with platinum and 5‐FU in patients whose tumors express programmed cell death‐ligand 1 (PD‐L1) with a combined positive score of ≥1.12 This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.